Virginie Siguret

Professor

Université Paris Descartes

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Virginie Siguret is a Professor at Paris Descartes University, France. Her research areas encompass anticoagulation therapy management, pharmacotherapy education, and the clinical implications of hematological disorders. Recent publications include studies on unfractionated heparin management, antithrombotic drug use in pharmacy education, and various aspects of coagulation disorders.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

Alexandre Mansour

FRANCE

View details

Carmelo Lafuente-Lafuente

Sorbonne Université

FRANCE

View details

Pr, Head of laboratory

Université Toulouse III - Paul Sabatier

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Virginie Siguret

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Results of an international survey on the management of therapeutic intensity unfractionated heparin: communication from the SSCs of the ISTH

Evaluation of the Inverted Classroom Approach in a Case-Study Course on Antithrombotic Drug Use in a PharmD Curriculum: French Monocentric Randomized Study

Cerebral Venous Thrombosis and Nitrous Oxide Intoxication: Report of Two Cases and Review of the Literature

Effect of Selective Serotonin Reuptake Inhibitors on Coagulation: Fact or Fiction?

Moyamoya Angiopathy and Antiphospholipid Antibodies: A Coincidental Association?

Management of Therapeutic-intensity Unfractionated Heparin: A Narrative Review on Critical Points

Comparisons between diluted thrombin time, ecarin chromogenic assays, and UPLC–MS for plasma level dabigatran quantification: Results from DRIVING study

Practical Nomogram Predicting Apixaban or Rivaroxaban Concentrations from Low-Molecular-Weight Heparin Anti-Xa Values: Special Interest in Acute Ischemic Stroke Patients

Assessment of DOAC in GEriatrics (ADAGE study): rivaroxaban/apixaban concentrations and thrombin generation profiles in NVAF very elderly patients

Relapse of acquired von Willebrand syndrome in a patient non-compliant with Crohn's disease

GFHT proposals on the practical use of argatroban — With specifics regarding vaccine-induced immune thrombotic thrombocytopaenia (VITT)

Is platelet function testing at the acute phase under P2Y12 inhibitors helpful in predicting bleeding in real-life patients with acute coronary syndrome? The AVALANCHE study

Bleeding and Thrombosis: Insights into Pathophysiology of <i>Bothrops</i> Venom-Related Hemostasis Disorders

Induced forms of α2-macroglobulin neutralize heparin and direct oral anticoagulant effects

Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021)

Study of thrombin generation with St Genesia to evaluate xaban pharmacodynamics: Analytical performances over 18 months

Collaborators (8)

Alexandre Mansour

Carmelo Lafuente-Lafuente

Jean-Philippe Chippaux

Georges JOURDI

Jerrold Levy

Thomas Pierre Lecompte

Chloe James

Pierre SIE

Make your next move.